← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT05749302
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
Trial Parameters
Condition Malignancy
Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-01-08
Completion 2025-03-08
Interventions
Al18F-NOTA-FAPI
Brief Summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-NOTA-FAPI PET/CT in patients with malignant tumors expressing fibroblast-activated proteins
Eligibility Criteria
Inclusion Criteria: * Patients with suspected or clearly diagnosed Malignant Tumors Expressing Fibroblast-activated Proteins * signed written consent. * Willing and able to cooperate with all projects in this study. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Related Trials
NCT05770544
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients
View Trial →
NCT06988475
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregula
View Trial →
NCT05749302
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
View Trial →